T-cell-mediated rejection of the kidney in the era of donor-specific antibodies: diagnostic challenge and clinical significance

Current Opinion in Organ Transplantation

Volumn 20, Issue 3, 2015, Pages 325-332

  Randhawa, Parmjeet ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody; Donor specific antibodies; Mixed rejection; Rejection; T cells

Indexed keywords

ACUTE GRAFT REJECTION; ANTIBODY MEDIATED REJECTION; ARTERY DISEASE; CLINICAL MONITORING; CLINICAL OUTCOME; ENDARTERITIS; GLOMERULOPATHY; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; HYPERACUTE GRAFT REJECTION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; KIDNEY DONOR; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T CELL MEDIATED REJECTION; T LYMPHOCYTE; ADVERSE EFFECTS; DONOR; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION;

ANTIBODY;

ANTIBODIES; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; T-LYMPHOCYTES; TISSUE DONORS;

EID: 84969308100     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0000000000000189     Document Type: Review

References (54)

1. Solez K, Axelsen RA, Benediktsson H, et al. International standardization of criteria for the histologic diagnosis of renal allograft rejection: the Banff working classification of kidney transplant pathology. Kidney Int 1993; 44:411–422.
2. Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med 1969; 280:735–739.
3. Trpkov K, Campbell P, Pazderka F, et al. Pathologic features of acute renal allograft rejection associated with donor-specific antibody, analysis using the Banff grading schema. Transplantation 1996; 61:1586–1592.
4. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55:713–723.
5. Halloran PF, Wadgymar A, Ritchie S, et al. The significance of the anticlass I antibody response. I Clinical and pathologic features of anticlass I-mediated rejection. Transplantation 1990; 49:85–91.
6. Feucht HE, Felber E, Gokel MJ, et al. Vascular deposition of complement-split products in kidney allografts with cell-mediated rejection. Clin Exp Immunol 1991; 86:464–470.
7. Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574–582.
8. Solez K, Colvin RB, Racusen LC, et al. Banff’05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (’CAN’). Am J Transplant 2007; 7:518–526.
9. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8:753–760.
10. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388–399.
11. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoral rejection. Transplantation 2012; 93:41–46.
12. Sellares J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388–399.
13. Sis B, Jhangri GS, Riopel J, et al. A new diagnostic algorithm for antibody-mediated microcirculation inflammation in kidney transplants. Am J Transplant 2012; 12:1168–1179.
14. Lefaucheur C, Loupy A, Vernerey D, et al. Antibody-mediated vascular && rejection of kidney allografts: a population-based study. Lancet 2013; 381:313–319. This study highlights two different forms of TCMR: one mediated by T-cells and the other by antibodies. Each needs its own specific therapeutic intervention.
15. Batal I, Lunz JG 3rd, Aggarwal N, et al. A critical appraisal of methods to grade transplant glomerulitis in renal allograft biopsies. Am J Transplant 2010; 10:2442–2452.
16. Haas M, Sis B, Racusen LC, et al. Banff 2013 meeting report: inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014; 14:272–283.
17. Gago M, Cornell LD, Kremers WK, et al. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012; 12: 1199–1207.
18. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527–535.
19. Naesens M, Kuypers DR, De Vusser K, et al. Chronic histological damage in & early indication biopsies is an independent risk factor for late renal allograft failure. Am J Transplant 2013; 13:86–99. The authors show that even borderline T-cell infiltrates are associated with graft loss even if correction is made for the time of biopsy, and concurrent presence of ABMR.
20. Matignon M, Muthukumar T, Seshan SV, et al. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation 2012; 94: 603–611.
21. Sis B, Bagnasco SM, Cornell LD, et al. Isolated Endarteritis and Kidney && Transplant Survival: A Multicenter Collaborative Study. J Am Soc Nephrol 2014. [Epub ahead of print] This study demonstrates that T-cell-mediated arteritis can adversely affect graft survival even if there is minimal interstitial inflammation and tubulitis.
22. Wu KY, Budde K, Schmidt D, et al. Acute cellular rejection with isolated v-lesions is not associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations. Clin Transplant 2014; 28: 410–418.
23. Dorje C, Midtvedt K, Holdaas H, et al. Early versus late acute antibody-mediated && rejection in renal transplant recipients. Transplantation 2013; 96:79–84. This study describes a case series in which ABMR was almost universally accompanied by TCMR. The association becomes even stronger in biopsies performed late after transplantation.
24. Rodrigues CA, Franco MF, Cristelli MP, et al. Clinicopathological characteristics and effect of late acute rejection on renal transplant outcomes. Transplantation 2014; 98:885–892.
25. de Freitas DG, Sellares J, Mengel M, et al. The nature of biopsies with ‘‘borderline rejection’’ and prospects for eliminating this category. Am J Transplant 2012; 12:191–201.
26. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10:2066–2073.
27. Famulski KS, Reeve J, de Freitas DG, et al. Kidney transplants with progressing chronic diseases express high levels of acute kidney injury transcripts. Am J Transplant 2013; 13:634–644.
28. Subramanian V, Ramachandran S, Banan B, et al. Immune response to tissue-restricted self-antigens induces airway inflammation and fibrosis following murine lung transplantation. Am J Transplant 2014; 14:2359–2366.
29. Gloor JM, Sethi S, Stegall MD, et al. Transplant glomerulopathy: subclinical incidence and association with alloantibody. Am J Transplant 2007; 7:2124–2132.
30. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157–1167.
31. Kraus ES, Parekh RS, Oberai P, et al. Subclinical rejection in stable positive crossmatch kidney transplant patients: incidence and correlations. Am J Transplant 2009; 9:1826–1834.
32. Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11:2132–2143.
33. Kim JJ, Balasubramanian R, Michaelides G, et al. The clinical spectrum of de & novo donor-specific antibodies in pediatric renal transplant recipients. Am J Transplant 2014; 14:2350–2358. It is shown that DSA does not inexorably lead to graft loss. Antibody levels can fluctuate and be complicated by episodes of tubulitis that portends a bad outcome.
34. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7:2712–2722.
35. Woodle ES, Spargo B, Ruebe M, Charette J. Treatment of acute glomerular rejection with FK 506. Clin Transplant 1996; 10:266–270.
36. Robins HS, Campregher PV, Srivastava SK, et al. Comprehensive assessment of T-cell receptor beta-chain diversity in alpha beta T cells. Blood 2009; 114:4099–4107.
37. Bagai R, Valujskikh A, Canaday DH, et al. Mouse endothelial cells cross-present lymphocyte-derived antigen on class I MHC via a TAP1- and proteasome-dependent pathway. J Immunol 2005; 174:7711–7715.
38. Batal I, Azzi J, El-Haddad N, et al. Immunohistochemical markers of tissue injury in biopsies with transplant glomerulitis. Hum Pathol 2012; 43:69–80.
39. Gibson IW, Gwinner W, Brocker V, et al. Peritubular capillaritis in renal allografts: prevalence, scoring system, reproducibility and clinicopathological correlates. Am J Transplant 2008; 8:819–825.
40. Lefaucheur C, Nochy D, Hill GS, et al. Determinants of poor graft outcome in patients with antibody-mediated acute rejection. Am J Transplant 2007; 7:832–841.
41. Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11:56–65.
42. Matheson PJ, Dittmer ID, Beaumont BW, et al. The macrophage is the predominant inflammatory cell in renal allograft intimal arteritis. Transplantation 2005; 79:1658–1662.
43. Sellares J, de Freitas DG, Mengel M, et al. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. Am J Transplant 2011; 11:489–499.
44. Akalin E, Dinavahi R, Dikman S, et al. Transplant glomerulopathy may occur in the absence of donor-specific antibody and C4d staining. Clin J Am Soc Nephrol 2007; 2:1261–1267.
45. Papadimitriou JC, Drachenberg CB, Ramos E, et al. Antibody-mediated & allograft rejection: morphologic spectrum and serologic correlations in surveillance and for cause biopsies. Transplantation 2013; 95:128–136. This study illustrates how the diagnostic triad needed for a diagnosis of ABMR can not be easily applied to surveillance and for cause biopsies. Microvascular inflammation without DSA or C4d stain was seen in 17.5% of biopsies and may represent TCMR.
46. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of & donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013; 8:2141–2148.
47. These authors not the occurrence of chronic transplant glomerulopathy in DSA and C4d negative biopsies with increased T-cell transcripts suggesting an antibody-independent pathogenesis of this lesion.
48. Sis B, Campbell PM, Mueller T, et al. Transplant glomerulopathy, late antibody-mediated rejection and the ABCD tetrad in kidney allograft biopsies for cause. Am J Transplant 2007; 7:1743–1752.
49. Papadimitriou JC, Drachenberg CB, Munivenkatappa R, et al. Glomerular inflammation in renal allografts biopsies after the first year: cell types and relationship with antibody-mediated rejection and graft outcome. Transplantation 2010; 90:1478–1485.
50. Homs S, Mansour H, Desvaux D, et al. Predominant Th1 and cytotoxic phenotype in biopsies from renal transplant recipients with transplant glomerulopathy. Am J Transplant 2009; 9:1230–1236.
51. Baid-Agrawal S, Farris AB 3rd, Pascual M, et al. Overlapping pathways to transplant glomerulopathy: chronic humoral rejection, hepatitis C infection, and thrombotic microangiopathy. Kidney Int 2011; 80:879–885.
52. Hill GS, Nochy D, Bruneval P, et al. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22: 975–983.
53. Kotliar C, Juncos L, Inserra F, et al. Local and systemic cellular immunity in early renal artery atherosclerosis. Clin J Am Soc Nephrol 2012; 7:224–230.
54. Colvin RB, Cohen AH, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity, and clinical correlation. J Am Soc Nephrol 1997; 8:1930–1941.